 Zynerba Pharmaceuticals Inc NASDAQ: ZYNE has decided not to advance Zygel against developmental and epileptic encephalopathies DEE. The decision was in line with the feedback from the FDA, which indicated that the selection of a specific DEE syndrome would be required to support its clinical trials for a pediatric indication, the company said. 